Summary

Stroke prevention in atrial fibrillation is an evolving story and it is often predicted that the he new oral anticoagulants that are now reaching the market offer numerous advantages over vitamin K antagonists, including oral administration, therapeutic stability that does not require monitoring, once- or twice-daily administration, and a short half-life.